Skip to main content
. 2021 Nov 16;297(6):101420. doi: 10.1016/j.jbc.2021.101420

Figure 1.

Figure 1

The structure, purity, and stability of HER2/PD-L1 BsAb.A, BsAb is composed of intact trastuzumab IgG1 mAb and scFV fragments from anti-PD-L1 fused to the C-terminal of the trastuzumab Fc via a flexible (GGGGS)3 linker. B, BsAb and trastuzumab were analyzed by reduced and nonreduced SDS-PAGE. Lane 1, reduced trastuzumab; lane 2, reduced BsAb; lane 3, nonreduced trastuzumab; lane 4, nonreduced BsAb; M, Molecular weight markers. C, the purities of BsAb and trastuzumab analyzed by SEC-HPLC. D, comparing the thermostabilities of BsAb and trastuzumab by DSF analysis performed on a Bio-Rad real-time PCR instrument.